+1-800-267-5763
International Uveitis Study Group Document Collection About the Care of Uveitis Patients in the COVID-19 Pandemic
Canadian Eye and Tissue Bank Operational Status Update
March 24, 2020
| Province | Program Status March 24, 2020 |
| British Columbia | The Eye Bank of BC is continuing to recover, albeit at a reduced level. During this time, BC is deferring all respiratory-related deaths and those from ICUs; and will be asking supplemental Med/Soc questions (1. Has the donor been diagnosed with or suspected to have had COVID-19 in the past two months; 2. Has to donor had any contact with someone diagnosed with or suspected to have had COVID-19 in the past 28 days; 3) Did the donor have any of the following symptoms in the past 28 days: fever, dry cough, or shortness of breath; 4. Did the donor travel outside of Canada in the past 28 days; and 5. Did the donor have any contact with someone who travelled outside of Canada in the past 28 days). A positive response to Q#1 is an automatic deferral, positive responses for any other questions will be sent for a medical director consult. |
| Alberta North | CTC is still recovering tissue. Cornea transplants are on hold as an elective procedure, so CTC has no need to recover corneas. CTC is determining its approach to have emergent supply on hand but will likely continue with a limited recovery program in order to have corneas on hand for emergencies. |
| Alberta South | |
| Saskatchewan | Eye bank has suspended recovery. |
| Manitoba | Tissue Bank Manitoba: Currently business as usual. Remembering that we are a recovery agency & allograft distributor, not a source establishment, here is my update: Allograft Distribution: 0 = Surgeries canceled or delayed4 donors in the last 8 days (this is high for us, normally we do 4 a month –people are feeling very generous right now)Enhanced Covid-19 screening as per Health Canada, AATB etc. Experiencing slight delays at US border, but not significant enough to impact operations; 0 issues with materials or supplies; We are currently supplied for ~3 months.In anticipation of this event I increased our allograft inventory by ~25% three weeks ago, so no anticipated issues thereAll staff present and accounted for, not a single part-time/full-time staff member has requested leave for child care or other Modifications to our service are minimal: No visitors allowed in the facilityModified shift schedule to reduce the amount of people at work at one timeReduction on face-to-face meetings, any necessary huddles/meeting is held in lobby or from office door, where ample space is availableGeneral reminders around use of universal precautions At this time we are not planning to alter our services, however that status could change at any time as the situation evolves. We anticipate that this event will last for months and will continue to provide service as we are able. Misericordia Eye Bank Eye Bank is limiting recovery based on the Donor Assessment record and 28-day criteria of EBAA. Are being cautious with tissue recovery as we will need tissue for emergency cases when those occur. Frozen would be the first choice as we have a supply of frozen globes and amnion. |
| Ontario | Screening Changes: TGLN using 28 days threshold free of any respiratory symptoms, etc. Ocular Recovery: Eye Bank had a potential staff exposure so temporarily not receiving tissue. As of March 23rd Eye Bank is now prepared to receive tissue. TGLN working through recovery staff concerns before re-starting recoveries and providing education on the new screening. Expected date to re-start recoveries for emergency use is March 25 or 26 assuming decision to move forward. Recovery of whole globe to meet emergency ocular surgery needs using revised screening criteria. All other ocular recoveries deferred. Elective eye surgeries cancelled throughout the province. Recovery to be completed at TGLN’s surgical suite, not hospitals Multi Tissue Recovery: Recovery as in the past using revised screening criteria.Donations continue but reduced volume. Recovery completed at TGLN recovery suite, not hospitals. |
| Quebec | No tissue recovery is being performed at hospitals, donors are transported to our facilities to limit the travel and exposure of recovery staff. Staff are asked to stay home or are reassigned to other departments. Multi-tissue activity reduced to week-days only (recovery and processing day and evening shifts). Reduced but will ensure heart, skin and eye recovery.Will maintain a limited supply of cornea, mainly for urgent tissue requests.Hospitals have cancelled non-urgent surgeries, resulting in 25 corneal transplants cancelled this week. If the situation worsens the need for tissue will be minimal and the tissue bank will reduce its activities further and prioritize life-saving tissues (skin grafts and pediatric heart valves) It will be increasingly difficult to qualify tissue donors in those that have been infected or in contact with infected people. There is a recommendation to limit movement from one region to another within the province, and in the event, travel is prohibited, this will reduce the number of donors. Have added two new specific qualifying questions: have they been diagnosed or expected diagnosed with COVID 19 (28-day deferral) and has there been contact or have they been ordered to quarantine. Following the recommendation from Public Health, they will be modifying the deferral period to 14 days. |
| New Brunswick | As of Feb. 27th, new questions were added to the DRAI (in accordance to EBAA & AATB recommendations).On March 16th, under the guidance of our Medical Director, Dr Seamone, and in consultation with Nova Scotia Health’s Regional Tissue Bank (where most corneas recovered in NB are sent for processing and allocation), we suspended all ocular tissue recovery in consideration of the following: OR now being restricted to urgent and emergent cases only (hence no corneal transplant surgeries) and some frozen tissue being available (for tectonic use).The NBOTP-Ocular Division has no corneal tissue in the bank. Some NB tissue has been frozen and available from Regional Tissue Bank. For MS tissue, because of the same reductions taking place in NB’s Horizon Health Network (cancellation of elective surgeries) and the fact that, for NBOTP, Eye Bank Technicians are responsible to perform initial screening for MS tissue donors, under the guidance of our Medical Director, Dr Mitton, we have also decided to suspend MS tissue recoveries temporarily.We do have some tissues on inventory which can be shipped to NB facilities sill ordering these; our current inventory consisting mostly of bone products (cancellous chips, femoral & tibial struts, femoral heads, tricortical wedges, fibula segments, with some hemi-patellar tendons). |
| Nova Scotia | Has suspended all eye and tissue recovery as COVID continues to spread. Decision is based on risk assessment to staff, patients and in relation to utilization of resources.Bank PPE and supplies may be redirected to patient care. Suspension is expected to be extended as COVID continues to spread. |
New Recommendations Regarding Urgent and Nonurgent Patient Care from AAO
Due to the COVID-19 pandemic, the American Academy of Ophthalmology now finds it essential that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately.
We now live and practice in a critically different medical reality—a rapidly evolving viral pandemic that is projected to, if unchecked, kill millions of Americans and tens of millions around the world. Public health experts agree that we must do two things on an urgent basis:
First, we must reduce the risk of the SARS-CoV-2 virus transmission from human to human and the rate of new case development. Only in that way can we flatten the curve and not overwhelm our very limited supply of hospital beds, ICU beds, ventilators and extracorporeal membrane oxygenation (ECMO) machines. We have already hit that stage in a few hard-hit metropolitan areas.
Second, we must as a nation conserve needed disposable medical supplies and focus them to the hospitals where they are most needed.
This disease is now in every state and the number of new cases is currently doubling every one to two days. Already, a handful of our ophthalmologist colleagues have died from COVID-19. It is essential that we as physicians and as responsible human beings do what we can and must to reduce virus transmission and enhance our nation’s ability to care for those desperately ill from the disease. Public health experts unanimously agree that our window to modify the spread of disease is a narrow and closing one.
Accordingly, the American Academy of Ophthalmology strongly recommends that all ophthalmologists provide only urgent or emergent care. This includes both office-based care and surgical care. The Academy recognizes that “urgency” is determined by physician judgment and must always take into account individual patient medical and social circumstances. Each of us has a societal responsibility to not function as a vector of a potentially fatal disease—and one for which a widely available treatment or vaccine does not currently exist.
All other factors—business, finance, inconvenience, etc.—are remotely secondary. This is an existential crisis. We as physicians must respond to it and support our colleagues and our communities. Be safe.
Access Details
For additional information go to aao.org/coronavirus.
CMA Policy on Physician Health
This policy provides a series of broad, aspirational recommendations to help guide stakeholders at all levels of the health system to promote a healthy, vibrant, and engaged profession.
For more details visit the Canadian Medical Association website.
CMQ Regulation 2019
As you know, the College des médecins du Québec (CMQ) has approved a new regulation (Règlement sur la formation continue obligatoire des médecins), which came into force on January 1, 2019. The regulation stipulates that all physicians licensed in Quebec must report their continuing professional development (CPD) activities to the CMQ.
We want to reassure our Quebec members that COS accredited CPD activities are accredited through the Royal College Maintenance of Certification (MOC) Program and will qualify under the CMQ’s new requirements. This means you will still be able to meet your CPD requirements by participating in COS accredited CPD activities.
The Royal College has confirmed that physicians licensed in Quebec will be able to fulfil their new CMQ requirements through the Royal College MOC Program and they will not have to report CPD activities twice. To facilitate this, the Royal College is mapping their MOC requirements to the CMQ requirements, which are reported in hours rather than credits. After that, the Royal College will expand MAINPORT ePortfolio to ensure the reporting of MOC data is seamlessly aligned with the CMQ requirements and platform.
If you have any questions about the new regulation and the new CPD reporting requirements, please contact the CMQ at [email protected].
We have also curated the following list of resources about the new CMQ regulation:
- CMQ website: Formation continue obligatoire (French only): http://www.cmq.org/page/fr/formation-continue-obligatoire-intro.aspx.
- Royal College, Dialogue, December 2018, Quebec specialists: MOC cycles are changing — here’s what you need to know:
- Fédération des médecins specialists du Québec (FMSQ) webinar: Demystifying the Règlement sur la formation continue obligatoire des médecins: https://studiocast.ca/client/fmsq/event/5883/en/
- FMSQ, Le Spécialiste, December 2018, p. 15:
A message from the COS Maintenance of Certification (MOC) Committee:
Colin Mann (Chair), MD
Chloe Gottlieb, MD
Glen Hoar, MD
Phil Hooper, MD
Rob Schertzer, MD
COS and Canadian Corneal, External Disease and Refractive Surgery Society statement to CTV/W5
(April, 2019)
We are saddened about Jessica Starr’s death and convey our sympathy to her family, friends and all who are affected. According to the Centers for Disease Control and Prevention, suicide is one of the leading causes of death in the United States and one of the few that is rising. However, it cannot be reduced to any single cause, and there is no clinical evidence linking suicide to laser vision correction surgery.
Based on the 7,000+ studies conducted, the millions of satisfied patients and the successful twenty years in-market history, we are fully confident in the safety and efficacy of laser vision correction for qualified candidates.
The safety and the benefits of laser vision correction procedures have been recognized by organizations with the highest standards for safety and visual acuity — including the U.S. Military and NASA, who conducted their own independent research. Today, these organizations make laser vision correction procedures available to improve the vision of their most elite personnel, including sharpshooters and astronauts.
Not everyone is a candidate for laser vision correction and every individual must weigh the risks and benefits of an elective medical procedure. The Canadian Ophthalmological Society and the Canadian Cornea, External Diseases and Refractive Surgery Society actively support patient education efforts with the goal of ensuring those who are interested in laser vision correction get the information they need to make the right decision for themselves and their vision.
Anyone contemplating suicide or worried about a friend or loved one should contact the Canada Suicide Prevention Service (CSPS) at the following toll-free number: 1-833-456-4566. Services are available in English and French, 24 hours a day.
Medical use of cannabis for dry eye disease
November 2018
Background
The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.
The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.
Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.
Access Details
Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).
Medical use of cannabis for glaucoma
October 2018
Background
The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.
Access Details
Read the full policy statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS).
Micro-invasive or minimally invasive glaucoma surgery (2017)
Position Statement
(December 2017)
Summary
Current surgical treatments for glaucoma are aimed at reducing intraocular pressure (IOP) through decreasing aqueous inflow or enhancing of aqueous outflow and thereby reducing the risk of visual field loss. While trabeculectomy and implantation of glaucoma drainage devices are the standard and more commonly performed surgical interventions for glaucoma, they are often reserved for patients with uncontrolled moderate to severe disease, due to their higher risk of severe complications. The COS & CGS recognize that there is a gap in treatment options that exists between medical and traditional surgical interventions for patients with more mild to moderate forms of glaucoma who may not be optimally treated with the traditional standard of care. The surgical risk to benefit ratio would favour a safer procedure in these patients.
During the past decade, novel medical devices and procedures, collectively referred to as MIGS (micro-invasive or minimally invasive glaucoma surgery), have emerged and become available to Canadian patients. Their cardinal features include an ab interno approach, modest efficacy, high safety profile, rapid postoperative recovery and minimal tissue trauma. These procedures are designed to improve the safety of surgical intervention for glaucoma, while providing the efficacy needed to slow or halt glaucoma progression. The trade-off of having a safer surgical profile is that these procedures, at their current stage of development, are not as effective in reducing IOP as the standard glaucoma procedures.
Demonstrated benefits of MIGS include lowering IOP, reducing medication need, rapid post-operative recovery and minimal complications. Additional benefits that continue to be studied include the delay or prevention of more invasive glaucoma surgery, improvement of quality of life, reduction in number of doctor visits, cost-effectiveness, and prevention of vision loss.
Current indications for MIGS include patients undergoing cataract surgery and requiring medical glaucoma therapy; patients unable to tolerate or adhere to medical glaucoma therapy; and patients with intraocular pressure not sufficiently controlled by medical and/or laser therapy while not clearly requiring invasive surgeries such as trabeculectomy and glaucoma drainage devices. The majority of the MIGS procedures are not indicated for patients with angle closure glaucoma.
There is broad agreement among Canadian and international glaucoma specialists, based on current evidence and practice patterns, that MIGS do have a role in the glaucoma treatment algorithm. With the aging population at increased risk for glaucoma, coupled with limited healthcare resources, we support equitable access to innovative new technology such as MIGS. These newer surgical treatments can fill the gap in treatment that exists today, deliver better outcomes to patients, and ideally will aid in optimizing health system utilization. This position paper represents the current position of the COS and CGS regarding MIGS. Both societies support new and innovative technologies within Ophthalmology and will continue to monitor this evolving area of practice and update this position statement accordingly.
The COS and CGS are currently working together with the Canadian Agency for Drugs and Technologies in Health (CADTH) to determine the optimal use of MIGS for adults with glaucoma based on current evidence.
Access Details
Read the full Position Statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS)
COS-CGS Position Statement on MIGSDownload